Scottish National Blood Transfusion Service

Resolution Therapeutics Secures $83 Million to Advance Macrophage Therapy for End-Stage Liver Disease

8 months ago

• Resolution Therapeutics has secured $83 million in Series B financing to advance RTX001, a novel macrophage therapy, into clinical trials for end-stage liver disease. • The EMERALD Phase I/II trial, evaluating RTX001, is set to begin in the UK and Spain in Q4 2024, marking a significant step for this potential first-in-class treatment. • The funding will also support the expansion of Resolution's macrophage therapy platform into other inflammatory and fibrotic conditions, including graft-vs-host disease. • Paul Sekhri, a seasoned life sciences executive, has been appointed as Chair of the Board of Directors, bringing extensive experience to guide Resolution's growth.